Advertisement

Near Term Prospects for Broad Spectrum Amelioration of Cancer

  • Zheng CuiEmail author
Chapter

Abstract

If the impact of aging on cancer is to diminish an immune-based surveillance activity that naturally exists at a high level in young healthy humans, the solution to the problem of cancer could be to simply replenish such a lost activity in cancer patients with functionally validated agents that carry such an activity. Studies in my laboratory have shown that a profound cancer-killing activity (CKA) is present, surprisingly, in the previously overlooked granulocyte fraction of the innate cellular immune system of cancer-resistant mice. Granulocytes with high levels of CKA from cancer-resistant donor mice can be transferred into non-resistant recipients with advanced malignancy to effectively eradicate cancers. Human granulocytes also possess CKA, and CKA in both mouse and human granulocytes declines with age, consistent with the age-related increase in cancer incidence in both species. Furthermore, human CKA activity is low in cancer patients, and human cancer remissions have been associated with conditions that augment granulocyte function. Allogeneic granulocyte transfusion in humans is a safe, approved, and long-established procedure. Therefore, it is possible that transfusion of high CKA granulocytes in a human setting could be a highly effective and non-toxic therapy for human cancers, and a clinical trial of this concept is now beginning.

Keywords

Cancer Cell S180 Cell Live Cancer Cell Cancer Surveillance Kill Cancer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Alfaro G, Lomeli C, Ocadiz R, Ortega V, Barrera R, Ramirez M, Nava G (1992) Immunologic and genetic characterization of S180, a cell line of murine origin capable of growing in different inbred strains of mice. Vet Immunol Immunopathol 30:385–398PubMedCrossRefGoogle Scholar
  2. Barber GN (2001) Host defense, viruses and apoptosis. Cell Death Differ, 8: 113–126PubMedCrossRefGoogle Scholar
  3. Bartrons, R. and J. Caro (2007) Hypoxia, glucose metabolism and the Warburg’s effect. J Bioenerg Biomembr 39(3):223–229PubMedCrossRefGoogle Scholar
  4. Bodey B (2002) Spontaneous regression of neoplasms: new possibilities for immunotherapy. Expert Opin Biol Ther 2:459–476PubMedCrossRefGoogle Scholar
  5. Bickels J et al. (2002) Coley’s toxin: historical perspective. Isr Med Assoc J 4:471–472PubMedGoogle Scholar
  6. Brubaker LH, Essig LJ, Menge CE (1977) Neutrophil life span in paroxysmal nocturnal hemoglobinuria. Blood 50:657–662PubMedGoogle Scholar
  7. Busch W (1867) Aus der sitzung de medicinischen section vom. Berl Klin Wochenschr 5:137–145Google Scholar
  8. Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1–27Google Scholar
  9. Burnet FM (1971) Immunological surveillance in neoplasia. Transplant Rev 7:3–25PubMedGoogle Scholar
  10. Challis GB, Stam HJ (1990) The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol 29:545–550PubMedCrossRefGoogle Scholar
  11. Cohen S, Miller GE, Rabin BS (2001) Psychological stress and antibody response to mmunization: a critical review of the human literature. Psychosom Med 63:7–18PubMedGoogle Scholar
  12. Cole WH (1974) Spontaneous regression of cancer: the metabolic triumph of the host? Ann NY Acad Sci 230:111–141PubMedCrossRefGoogle Scholar
  13. Cole WH (1976) Spontaneous regression of cancer and the importance of finding its cause. Natl Cancer Inst Monogr 44:5–9PubMedGoogle Scholar
  14. Cole WH (1981) Efforts to explain spontaneous regression of cancer. J Surg Oncol 17:201–209PubMedCrossRefGoogle Scholar
  15. Coley WB (1893) The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop Relat Res 1991:3–11Google Scholar
  16. Coley WB (1908) The treatment of sarcoma with the mixed toxins of erysipelas and bacillus prodigious. Boston Med Surg J 158:175–182CrossRefGoogle Scholar
  17. Cui Z (2003) The winding road to the discovery of the SR/CR mice. Cancer Immun 3:14–23PubMedGoogle Scholar
  18. Cui Z et al. (2003) Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci USA 100:6682–6687PubMedCrossRefGoogle Scholar
  19. Dale DC, Boxer L, Liles WC (2008) The phagocytes: neutrophils and monocytes. Blood 112:935–945PubMedCrossRefGoogle Scholar
  20. Demaurex N et al. (1994) Characterization of receptor-mediated and store-regulated Ca2+ influx in human neutrophils. Biochem J 297:595–601PubMedGoogle Scholar
  21. De Smet, K. and R. Contreras, (2005) Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 27(18):1337–1347PubMedCrossRefGoogle Scholar
  22. Dhabhar FS (2000) Acute stress enhances while chronic stress suppresses skin immunity. The role of stress hormones and leukocyte trafficking. Ann NY Acad Sci 917:876–893PubMedCrossRefGoogle Scholar
  23. Doerfler W (1991) Patterns of DNA methylation–evolutionary vestiges of foreign DNA inactivation as a host defense mechanism. A proposal. Biol Chem Hoppe Seyler 372:557–564CrossRefGoogle Scholar
  24. Doerfler W (2005) On the biological significance of DNA methylation. Biochemistry (Mosc) 70:505–524CrossRefGoogle Scholar
  25. Doerfler W (2006) De novo methylation, long-term promoter silencing, methylation patterns in the human genome, and consequences of foreign DNA insertion. Curr Top Microbiol Immunol 301:125–175PubMedCrossRefGoogle Scholar
  26. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–48PubMedCrossRefGoogle Scholar
  27. Ellis TN, Beaman BL (2004) Interferon-gamma activation of polymorphonuclear neutrophil function. Immunology 112(1):2–12PubMedCrossRefGoogle Scholar
  28. Ehrlich P (1909) Ueber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr Geneeskd 5:273–290Google Scholar
  29. Epel ES (2009) Psychological and metabolic stress: a recipe for accelerated cellular aging? Hormones (Athens) 8:7–22Google Scholar
  30. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC (2008) Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 9:649–656PubMedCrossRefGoogle Scholar
  31. Funaro A et al. (2004) CD157 is an important mediator of neutrophil adhesion and migration. Blood 104:4269–4278PubMedCrossRefGoogle Scholar
  32. Ganz T et al. (1985) Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 76:1427–1435PubMedCrossRefGoogle Scholar
  33. Gifford R, Tristem M (2003) The evolution, distribution and diversity of endogenous retroviruses. Virus Genes 26:291–315PubMedCrossRefGoogle Scholar
  34. Gleeson M, Bishop NC (2000) Special feature for the Olympics: effects of exercise on the immune system: modification of immune responses to exercise by carbohydrate, glutamine and anti-oxidant supplements. Immunol Cell Biol 78:554–561PubMedCrossRefGoogle Scholar
  35. Gordon MY (1994) Origin and development of neutrophils. In: Hellewell PG, Williams TJ (eds) Immunopharmacology of Neutrophils. Academic Press Limited, London, pp. 1–26Google Scholar
  36. Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281:1309–1312PubMedCrossRefGoogle Scholar
  37. Hajek ER, Gutiérrez JR, Espinosa dGA (1984) Seasonality of mortality in human populations of Chile as related to a climatic gradient. Intl J Biometeorol 28:29–38CrossRefGoogle Scholar
  38. Hester JP et al. (1995) Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apher 10:188–1893PubMedCrossRefGoogle Scholar
  39. Heron M (2007) Deaths: leading causes for 2004. Natl Vital Stat Rep 56:1–95PubMedGoogle Scholar
  40. Hicks AM et al. (2006) Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA 103:7753–7758PubMedCrossRefGoogle Scholar
  41. Hill CP et al. (1991) Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science 251:1481–1485PubMedCrossRefGoogle Scholar
  42. Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–2676PubMedCrossRefGoogle Scholar
  43. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694PubMedCrossRefGoogle Scholar
  44. Koch J et al. (2008) Frequency of the cancer-resistant phenotype in SR/CR mice and the effect of litter seriation. In Vivo 22:565–569PubMedGoogle Scholar
  45. Langman L, Burr HS (1947) Electrometric studies in women with malignancy of cervix uteri. Science 105:209–210PubMedCrossRefGoogle Scholar
  46. Langman L, Burr HS (1949) A technique to aid in the detection of malignancy of the female genital tract. Am J Obstet Gynecol 57:274–281PubMedGoogle Scholar
  47. Lehrer RI et al. (1988) Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. J Clin Invest 81:1829–1835PubMedCrossRefGoogle Scholar
  48. Lehrer RI, Lichtenstein AK, Ganz T (1993) Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 11:105–128PubMedCrossRefGoogle Scholar
  49. Lehrer RI (2004) Primate defensins. Nat Rev Microbiol 2(9)727–738PubMedCrossRefGoogle Scholar
  50. Leonard B (2000) Stress, depression and the activation of the immune system. World J Biol Psychiatr 1:17–25CrossRefGoogle Scholar
  51. Lerner BH (2004) Sins of omission-Cancer research without informed consent. N Engl J Med 351:628–630PubMedCrossRefGoogle Scholar
  52. Lichtenstein AK et al. (1988) Synergistic cytolysis mediated by hydrogen peroxide combined with peptide defensins. Cell Immunol 114:104–116PubMedCrossRefGoogle Scholar
  53. Maksakova IA et al. (2006) Retroviral elements and their hosts: insertional mutagenesis in the mouse germ line. PLoS Genet 2:e2PubMedCrossRefGoogle Scholar
  54. Maksakova IA, Mager DL, Reiss D (2008) Keeping active endogenous retroviral-like elements in check: the epigenetic perspective. Cell Mol Life Sci 65:3329–3347PubMedCrossRefGoogle Scholar
  55. Matsumoto M et al. (2004) Toll-like receptor 3: a link between toll-like receptor, interferon and viruses. Microbiol Immunol 48:147–154PubMedGoogle Scholar
  56. McEwen BS (2000) The neurobiology of stress: from serendipity to clinical relevance. Brain Res 886:172–189PubMedCrossRefGoogle Scholar
  57. McLoughlin RM et al. (2004) Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol 172:5676–83PubMedGoogle Scholar
  58. Mikkelsen JG, Pedersen FS (2000) Genetic reassortment and patch repair by recombination in retroviruses. J Biomed Sci 7:77–99PubMedCrossRefGoogle Scholar
  59. Moore AE, Rhoads CP, Southam CM (1957) Homotransplantation of human cell lines. Science 125:158–160PubMedCrossRefGoogle Scholar
  60. Nathan C (2006) Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6:173–182PubMedCrossRefGoogle Scholar
  61. Nickelsen K (2007) Otto Warburg’s first approach to photosynthesis. Photosynth Res 92:109–120PubMedCrossRefGoogle Scholar
  62. Papac RJ (1996) Spontaneous regression of cancer. Cancer Treat Rev 22:395–423PubMedCrossRefGoogle Scholar
  63. Papac RJ (1998) Spontaneous regression of cancer: possible mechanisms. In Vivo 12:571–578PubMedGoogle Scholar
  64. Preminger BA (2002) The case of Chester M. Southam: research ethics and the limits of professional responsibility. Pharos Alpha Omega Alpha Honor Med Soc 65(2):4–9PubMedGoogle Scholar
  65. Pruett SB (2001) Quantitative aspects of stress-induced immunomodulation. Int Immunopharmacol 1:507–520PubMedCrossRefGoogle Scholar
  66. Richardson MA et al. (1999) Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med 5:42–47PubMedGoogle Scholar
  67. Rice WG et al. (1987) Defensin-rich dense granules of human neutrophils. Blood 70:757–765PubMedGoogle Scholar
  68. Schiffer CA, Aisner J, Wiernik PH (1977) Current status of granulocyte transfusion therapy. Prog Clin Biol Res 13:281–292Google Scholar
  69. Schiffer CA (1979) Filtration leukapheresis: summary and perspectives. Exp Hematol 7(4 Suppl):42–47PubMedGoogle Scholar
  70. Schiffer CA (1983) Granulocyte transfusion therapy. Cancer Treat Rep 67:113–119PubMedGoogle Scholar
  71. Selsted ME, Harwig SS (1989) Determination of the disulfide array in the human defensin HNP-2. A covalently cyclized peptide. J Biol Chem 264:4003–4007PubMedGoogle Scholar
  72. Silva JC, Loreto EL, Clark JB (2004) Factors that affect the horizontal transfer of transposable elements. Curr Issues Mol Biol 6:57–71PubMedGoogle Scholar
  73. Southam CM, Moore AE, Rhoads CP (1957) Homotransplantation of human cell lines. Science 125:158–160PubMedCrossRefGoogle Scholar
  74. Southam CM (1958) Homotransplantation of human cell lines. Bull N Y Acad Med 34:416–423PubMedGoogle Scholar
  75. Southem CM, Moore AE (1958) Induced immunity to cancer cell homografts in man. Ann N Y Acad Sci 73:635–653Google Scholar
  76. Starnes CO (1992) Coley’s toxins in perspective. Nature 357:11–12PubMedCrossRefGoogle Scholar
  77. Stefanski V (2001) Social stress in laboratory rats: behavior, immune function, and tumor metastasis. Physiol Behav 73:385–391PubMedCrossRefGoogle Scholar
  78. Stoll BA (1992) Spontaneous regression of cancer: new insights. Biotherapy 4:23–30PubMedCrossRefGoogle Scholar
  79. Sverdlov ED (1998) Perpetually mobile footprints of ancient infections in human genome. FEBS Lett 428:1–6PubMedCrossRefGoogle Scholar
  80. Thomas L (1959) Discussion of Medawar reactions to homologous tissue antigens in relation to hypersensitivity. In: Lawrence H (ed) Cellular and Humoral Aspects of the Hypersensitivity States. Paul Hoeberg, New YorkGoogle Scholar
  81. Tsung K, Norton JA (2006) Lessons from Coley’s Toxin. Surg Oncol 15:25–28PubMedCrossRefGoogle Scholar
  82. Uematsu S, Akira S (2007) Toll-like receptors and Type I interferons. J Biol Chem 282:15319–15323PubMedCrossRefGoogle Scholar
  83. Unknown author (1957) Cancer volunteers. TIME (http://www.time.com/time/magazine/article/0,9171,936841,00.html)
  84. Villeneuve PJ, Mao Y (1994) Lifetime probability of developing lung cancer, by smoking status, Canada. Can J Pub Health 85:385–388Google Scholar
  85. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H (2006) Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 103:1480–1485PubMedCrossRefGoogle Scholar
  86. Warburg O (1920) Uber die Geschwindigkeit der photochemischen Kohlensaurezersetzung in lebenden Zellen. Biochem Z 103:188–217Google Scholar
  87. Warburg O (1956a) On the origin of cancer cells. Science 123:309–314PubMedCrossRefGoogle Scholar
  88. Warburg O (1956b) On respiratory impairment in cancer cells. Science 124:269–270PubMedGoogle Scholar
  89. Waterston RH et al. (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420:520–562PubMedCrossRefGoogle Scholar
  90. White SH, Wimley WC, Selsted ME (1995) Structure, function, and membrane integration of defensins. Curr Opin Struct Biol 5:521–527PubMedCrossRefGoogle Scholar
  91. Wiemann B, Starnes CO (1994) Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 64:529–564PubMedCrossRefGoogle Scholar
  92. Witko-Sarsat V et al. (2000) Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 80:617–653PubMedCrossRefGoogle Scholar
  93. Zacharski LR, Sukhatme VP (2005) Coley’s toxin revisited: immunotherapy or plasminogen activator therapy of cancer? J Thromb Haemost 3:424–427PubMedCrossRefGoogle Scholar
  94. Zanetti M, Gennaro R, Romeo D (1995) Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374: 1–5PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  1. 1.Section of Tumor Biology, Department of PathologyWake Forest University School of MedicineWinston-SalemUSA

Personalised recommendations